20 research outputs found
Location and type of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
Background: Mutations of isocitrate dehydrogenase 1 and 2 are novel common genetic alterations identified in acute myeloid leukemia.
Aims: To investigate the frequency, clinical associations and prognostic effect of isocitrate dehydrogenase 1 and 2 mutations together, followed by a detailed investigation of particular mutations.
Methods: A consecutive cohort of 376 patients diagnosed with acute myeloid leukemia were enrolled to compare clinical characteristics. Prognostic impact was analyzed for 314 patients younger than 60 years treated with curative intention. Isocitrate dehydrogenase 1 and 2 mutations were screened using allele-specific PCR and high resolution melting, followed by a confirmatory sequencing.
Results: Isocitrate dehydrogenase (IDH) 1 and 2 mutations were mutually exclusive, detected in 8.5% and 7.5% of the cases respectively. Presence of mutations was associated with older age (p=0.001), higher platelet count (p=0.001), intermediate risk karyotype (p<0.0001), nucleophosmin1 mutation (p=0.022), and with lower mRNA expression level of ABCG2 gene (p=0.006), as compared to mutation negative cases. Remission, relapse rates and overall survival were not different in IDH-mutation positive patients. Interestingly, particular mutations differred in association with nucleophosmin1 mutation: co-occurrence was observed in 14.3% of R132C vs. 70% of R132H carriers (p=0.02); and in 47.4% of R140Q vs. 0% R172K carriers (p=0.02) of IDH1 and IDH2 genes, respectively. R132H negatively influenced overall survival compared to isocitrate dehidrogenase 1 and 2 negative (p=0.02) or to R132C (p=0.019) patients.
Conclusions: IDH mutations are frequent recurrent mutations in acute myeloid leukemia. Although a general common pathogenetic role is proposed, our results indicate that differences in clinical characteristics and treatment outcome may exist among disctinct mutations of both genes
NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients
Lycopene: total-scale literature landscape analysis of a valuable nutraceutical with numerous potential applications in the promotion of human and animal health
Lycopene intake from tomatoes and other food sources has multiple potential health benefits. This report aimed to evaluate the current research literature on lycopene concerning human and animal health. The electronic Web of Science Core Collection database was searched with (lycopene*) AND (health* OR illness* OR disease* OR medic* OR pharma* OR drug* OR therap*). The resulted 3972 papers were analyzed with the aid of bibliometric software. Besides the United States, the lycopene papers received global contributions, particularly from China, Italy, India, and Spain. Examples of frequently mentioned chemicals/chemical classes were carotenoid, beta carotene, alpha carotene, beta cryptoxanthin, and alpha tocopherol. Examples of frequently mentioned medical conditions were prostate cancer, cardiovascular disease, and obesity. Published scientific articles reveal the diverse potential of lycopene in prompting human and animal health, and the knowledge on the bioactivities of this phytoche(undefined)info:eu-repo/semantics/publishedVersio
Screening the Expression of ABCB6 in Erythrocytes Reveals an Unexpectedly High Frequency of Lan Mutations in Healthy Individuals
Lan is a high-incidence blood group antigen expressed in more than 99.9% of the population. Identification of the human ABC transporter ABCB6 as the molecular basis of Lan has opened the way for studies assessing the relation of ABCB6 function and expression to health and disease. To date, 34 ABCB6 sequence variants have been described in association with reduced ABCB6 expression based on the genotyping of stored blood showing weak or no reactivity with anti-Lan antibodies. In the present study we examined the red blood cell (RBC) surface expression of ABCB6 by quantitative flow cytometry in a cohort of 47 healthy individuals. Sequencing of the entire coding region of the ABCB6 gene in low RBC ABCB6 expressors identified a new allele (IVS9+1G>A, affecting a putative splice site at the boundary of exon 9) and two nonsynonymous SNPs listed in the SNP database (R192Q (rs150221689) and G588 S (rs145526996)). The R192Q mutation showed co-segregation with reduced RBC ABCB6 expression in a family, and we found the G588 S mutation in a compound heterozygous individual with undetectable ABCB6 expression, suggesting that both mutations result in weak or no expression of ABCB6 on RBCs. Analysis of the intracellular expression pattern in HeLa cells by confocal microscopy indicated that these mutations do not compromise overall expression or the endolysosomal localization of ABCB6. Genotyping of two large cohorts, containing 235 and 1039 unrelated volunteers, confirmed the high allele frequency of Lan-mutations. Our results suggest that genetic variants linked to lower or absent cell surface expression of ABCB6/Langereis may be more common than previously thought.This work was supported by the Lendulet Program of the Hungarian Academy of Sciences (GS), OTKA 83533 and by the Polish POIG grant 01.01.02-10-005/08 TESTOPLEK, supported by the EU through the European Regional Development Fund. Hajnalka Andrikovics is a recipient of the Janos Bolyai Research Scholarship from the Hungarian Academy of Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Dr. Camilo Toro and Dr. William Gahl of the NIH
Undiagnosed Diseases Program for an affected patient specimen; that
work was supported by the Intramural Research Program of the National
Human Genome Research Institute and the Office of the Director of the
NIH. We thank Lionel Arnaud (National Institute of Blood Transfusion
(INTS), Paris, France) for helpful discussions
Digital health and mobile health: a bibliometric analysis of the 100 most cited papers and their contributing authors
Aim: This study aimed to identify and analyze the top 100 most cited digital health and mobile health (m-health) publications. It could aid researchers in the identification of promising new research avenues, additionally supporting the establishment of international scientific collaboration between interdisciplinary research groups with demonstrated achievements in the area of interest. Methods: On 30th August, 2023, the Web of Science Core Collection (WOSCC) electronic database was queried to identify the top 100 most cited digital health papers with a comprehensive search string. From the initial search, 106 papers were identified. After screening for relevance, six papers were excluded, resulting in the final list of the top 100 papers. The basic bibliographic data was directly extracted from WOSCC using its “Analyze” and “Create Citation Report” functions. The complete records of the top 100 papers were downloaded and imported into a bibliometric software called VOSviewer (version 1.6.19) to generate an author keyword map and author collaboration map. Results: The top 100 papers on digital health received a total of 49,653 citations. Over half of them (n = 55) were published during 2013–2017. Among these 100 papers, 59 were original articles, 36 were reviews, 4 were editorial materials, and 1 was a proceeding paper. All papers were written in English. The University of London and the University of California system were the most represented affiliations. The USA and the UK were the most represented countries. The Journal of Medical Internet Research was the most represented journal. Several diseases and health conditions were identified as a focus of these works, including anxiety, depression, diabetes mellitus, cardiovascular diseases, and coronavirus disease 2019 (COVID-19). Conclusions: The findings underscore key areas of focus in the field and prominent contributors, providing a roadmap for future research in digital and m-health
Effect of Dried Apple Pomace (DAP) as a Feed Additive on Antioxidant System in the Rumen Fluid
The study aimed to evaluate the effect of dried apple pomace (DAP) as a feed additive on the enzymatic activity and non-enzymatic compounds belonging to the antioxidant system in cattle rumen fluid. The experiment included 4 Polish Holstein–Friesian cannulated dairy cows and lasted 52 days. The control group was fed with the standard diet, while in the experimental group, 6% of the feedstuff was replaced by dried apple pomace. After the feeding period, ruminal fluid was collected. The spectrophotometric technique for the activity of lysosomal enzymes, the content of vitamin C, polyphenols, and the potential to scavenge the free DPPH radical was used. The enzyme immunoassay tests (ELISA) were used to establish the activity of antioxidants enzymes and MDA. Among the rumen aminopeptidases, a significant reduction (p < 0.01) from 164.00 to 142.00 was observed for leucyl-aminopeptidase. The activity of glycosidases was decreased for HEX (from 231.00 to 194.00) and β-Glu (from 1294.00 to 1136.00), while a significant statistically increase was noticed for BGRD (from 31.10 to 42.40), α-Glu (from 245.00 to 327.00), and MAN (from 29.70 to 36.70). Furthermore, the activity of catalase and GSH (p < 0.01) was inhibited. In turn, the level of vitamin C (from 22.90 to 24.10) and MDA (from 0.36 to 0.45) was statistically higher (p < 0.01). The most positive correlations were observed between AlaAP and LeuAP (r = 0.897) in the aminopeptidases group and between β-Gal and MAN (r = 0.880) in the glycosidases group. Furthermore, one of the most significant correlations were perceived between SOD and AlaAP (r = 0.505) and AcP (r = 0.450). The most negative correlation was noticed between α-Gal and DPPH (r = −0.533) based on these observations. Apple pomace as a feed additive has an influence on lysosomal degradation processes and modifies oxidation–reduction potential in the rumen fluid. Polyphenols and other low-weight antioxidant compounds are sufficient to maintain redox balance in the rumen
Pedigrees of two families carrying different ABCG2 premature stop mutations – co-segregation of the heterozygous mutation with reduced erythrocyte ABCG2 expression levels.
<p>Blood samples obtained from the 14 family members of the two healthy volunteer probands, carrying the premature stop mutations (see Fig. 3 -indicated with arrowheads) were analyzed for ABCG2 expression and the respective mutations. The RBC-G2 factor values, reflecting ABCG2 expression in erythrocytes, are shown in parentheses. Family members not available for blood donation are labeled by N.A.</p
Expression Levels of the ABCG2 Multidrug Transporter in Human Erythrocytes Correspond to Pharmacologically Relevant Genetic Variations
<div><p>We have developed a rapid, simple and reliable, antibody-based flow cytometry assay for the quantitative determination of membrane proteins in human erythrocytes. Our method reveals significant differences between the expression levels of the wild-type ABCG2 protein and the heterozygous Q141K polymorphic variant. Moreover, we find that nonsense mutations on one allele result in a 50% reduction in the erythrocyte expression of this protein. Since ABCG2 polymorphisms are known to modify essential pharmacokinetic parameters, uric acid metabolism and cancer drug resistance, a direct determination of the erythrocyte membrane ABCG2 protein expression may provide valuable information for assessing these conditions or for devising drug treatments. Our findings suggest that erythrocyte membrane protein levels may reflect genotype-dependent tissue expression patterns. Extension of this methodology to other disease-related or pharmacologically important membrane proteins may yield new protein biomarkers for personalized diagnostics.</p> </div
ABCG2 is differentially expressed in the red blood cells of individuals carrying homozygous wild-type, heterozygous polymorphic or premature stop codon mutant ABCG2 alleles.
<p>Boxplot presentation showing the median and the 25–75<sup>th</sup> percentiles, whiskers represent 10–90<sup>th</sup> percentiles. ABCG2 expression is calculated based on the combined reactivity of anti-ABCG2 mAbs (RBC-G2 factor – see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0048423#s2" target="_blank">Methods</a>). Labels: individuals carrying wild-type ABCG2 (WT), polymorphic (Q141K, V12M) ABCG2 alleles, or a heterozygous stop mutation (STOP).</p